Agreement ensures that clients can access Novotech’s early to late-phase CRO services across Europe
News
AlzeCure begins Alzheimer’s therapy development phase
Candidate will go through the development programme, which includes safety and tolerability studies
Pheno and UCB reveal neurodegenerative disease programme agreement
Global preclinical programme has the potential for disease modifying therapeutics
Artificial pancreas technology set to change lives
Emerging technology could help patients who are unable to manage their type 1 diabetes
SIFI and Avanzanite announce AKANTIOR agreement
Partnership offers treatment access to hundreds of patients across several European countries
NHS Confederation responds to Prime Minister’s promise of NHS support
New financial assistance emerges as UK Government announces imminent discharge fund
AstraZeneca makes CinCor Pharma acquisition
Agreement involves access to global rights of blood pressure lowering therapy baxdrostat
Transgene receives approval to begin oncolytic virus trial
Study will evaluate the intravenous administration of company’s multi-armed immunotherapy
BioNTech forms cancer immunotherapies partnership with UK Government
Collaboration will focus on providing up to 10,000 patients with personalised mRNA by 2030
SanegeneBio and Orbit join forces to establish targeting peptides
Agreement covers cell-based studies, with an additional option to further develop screening activities
Mission Therapeutics concludes clinical assessment for lead DUB inhibitor
Safety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met
Janssen submits marketing application for talquetamab
European Medicines Agency will consider therapy for the treatment of patients with multiple myeloma
Antibody discovered by RQ Bio enters pivotal research phase
AstraZeneca trial will study activity of AZD5156 which includes monoclonal antibody discovered by RQ Bio
Valneva delivers additional data for COVID-19 booster vaccine
Company has reported booster details from a study of its inactivated COVID-19 candidate
Orion and Alligator reveal second stage of immuno-oncology research collaboration
Second study will develop a bispecific antibody with potential applications in solid tumours
